15
azathioprine By Dr Saad I Al Mohizea March 2006

Azathioprine

  • Upload
    fgg-fgg

  • View
    13

  • Download
    2

Embed Size (px)

DESCRIPTION

derma

Citation preview

Page 1: Azathioprine

azathioprine

ByDr Saad I Al MohizeaMarch 2006

Page 2: Azathioprine

azathioprine

Licensed indications include dermatomyositis, SLE and pemphigus vulgaris Non licensed include atopic dermatitis Chronic actinic dermatitisPyoderma gangrenosumPityriasis rubra pilarisWegener's granulomatosisCutaneous vasculitisPsoriasisLichen planusphotodermatosis

Page 3: Azathioprine

Azathioprine

Azathioprine is a prodrug Azathioprine is an imidazole derivative

of 6-mercaptopurine (6-MP) purine analogue. azathioprine is rapidly and almost

completely absorbed from the gut. No azathioprine crosses the blood–brain

barrier but crosses the palcenta

Page 4: Azathioprine
Page 5: Azathioprine

contraindications

unknown TPMT status Very low or absent TPMT activity hypersensitivity to azathioprine (or 6-MP) pregnant or hope to become pregnant in the near

future (except where benefit may outweigh risk) breast feeding Concurrent allopurinol treatment Concurrent malignant disease progression Renal or hepatic insufficiency (relative

contraindication)

Page 6: Azathioprine

Dose

The recommended dosage of azathioprine for dermatological indications is 1–3 mg/ kg 1 daily

If no improvement occurs in the patient's condition within 3 months, consideration should be given to withdrawing azathioprine.

Lower dose in elderly

Page 7: Azathioprine

Monitoring for azathioprine toxicity

•Weekly monitoring of CBC and LFTs for the first 4 weeks of therapy, or until the maintenance dose is achieved

reducing to a minimum of once every 3 months for the duration of therapy

•More frequent monitoring of FBC and LFTs is advised in patients with hepatic or renal impairment, in the elderly and in those treated with high doses of azathioprine•Increase in dosage of azathioprine should be accompanied by return to weekly FBC and LFTs for 4 weeks

reducing to a minimum of once monthly or every 2 months for the duration of therapy

Page 8: Azathioprine

susceptibility to infection

Azathioprine in combination with prednisolone is associated with an increased risk of infection, which may be fatal in the elderly.

Live vaccines are contraindicated for patients receiving azathioprine

Killed vaccines may elicit a diminished immune response in patients receiving azathioprine

Page 9: Azathioprine

Azathioprine-related malignancy

long-term treatment with azathioprine for rheumatoid arthritis showed an increased rate of lymphoma which was estimated at one case of lymphoma per 1000 patient years of azathioprine treatment

Despite this, reports of skin malignancy in patients receiving long-term azathioprine monotherapy are rare, suggesting that the risk, if it exists, is probably small.

Page 10: Azathioprine

Reported malignancies

More with rheumatoid arthritis and renal transplant patients

Only skin cancer in dermatologyLymphomaReal cell CASqamus cell CAKaposi

Page 11: Azathioprine

Azathioprine-induced hypersensitivity reactions

Idiosyncratic hypersensitivity reactions with azathioprine are recognized, but are rare.

Manifestations include nausea, diarrhoea and vomiting, malaise, dizziness, fever, rigors, rashes (urticarial, maculopapular and vasculitic) and even circulatory collapse

Page 12: Azathioprine

bone marrow suppression

LeukopeniaThrombocytopeniaLymphopenia

Other side effects:HepatotoxicityGI upsetAcute pancreatitis

Page 13: Azathioprine

Patient information

Azathioprine has a slow onset of action seek medical attention if they develop unexplained

bruising, sore throat, high fever or jaundice. seek immediate attention if they come into contact with

someone who has chickenpox or shingles. not to be given live vaccines There may be a small increase in the risk of

malignancy they should be warned of drug interaction Pregnancy should be avoided sudden onset of abdominal pain may be due to

pancreatitis

Page 14: Azathioprine

Drug interaction

Allopurinol inhibits the enzyme xanthine oxidase Sulfasalazine inhibits TPMT activity Warfarin. The anticoagulant effect may be impaired by

azathioprine. Myelosuppressive drugs such as penicillamine and co-

trimoxazole should be avoided due to the possibility of inducing serious haematological toxicity.

Angiotensin-converting enzyme inhibitors have been reported to induce severe leucopenia in patients taking azathioprine.

Live vaccines are contraindicated on theoretical grounds in patients taking azathioprine.

Page 15: Azathioprine